Featuring perspectives from Dr Sara M Tolaney, including the following topics:
- Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)
- Managing brain metastases in triple-negative breast cancer (6:30)
- EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)
- PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)